TRODELVY

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Israel, Italy, Lithuania, Poland, Romania, Turkey, UK.

Active ingredients

The drug TRODELVY contains one active pharmaceutical ingredient (API):

1	Sacituzumab govitecan UNII M9BYU8XDQ6 - SACITUZUMAB GOVITECAN
	Sacituzumab govitecan binds to Trop-2-expressing cancer cells and is internalised with the subsequent release of SN-38 from a hydrolysable linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell death.
	Read more about Sacituzumab govitecan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TRODELVY Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)
TRODELVY Powder for solution for infusion	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX17		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX17

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1867800
FI	Lääkealan turvallisuus- ja kehittämiskeskus	159417
FR	Base de données publique des médicaments	67719704
IL	מִשְׂרַד הַבְּרִיאוּת	9256
IT	Agenzia del Farmaco	049780012
LT	Valstybinė vaistų kontrolės tarnyba	1093692
PL	Rejestru Produktów Leczniczych	100460464
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68365001
TR	İlaç ve Tıbbi Cihaz Kurumu	8698760790310
US	FDA, National Drug Code	55135-132